Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

VCYT

Veracyte Inc

Dec 13 • 04:00PM ET

43.22

Dollar change -1.18
Percentage change -2.66	%

Healthcare • Diagnostics & Research • USA • NASD

Peers: EXAS ILMN GH BIO NTRA MYGN CDNA QGEN FLGT CRL

| Held by: ARKK IWM VTI VB ARKG XBI VXF VBK IWN IBB

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.14	Insider Own	1.43%	Shs Outstand	77.49M	Perf Week	-2.06%
Market Cap	3.26B	Forward P/E	69.04	EPS next Y	0.63	Insider Trans	-13.02%	Shs Float	76.39M	Perf Month	9.33%
Income	-9.27M	PEG	-	EPS next Q	0.11	Inst Own	106.25%	Short Float	3.88%	Perf Quarter	28.52%
Sales	425.33M	P/S	7.67	EPS this Y	135.29%	Inst Trans	3.02%	Short Ratio	3.72	Perf Half Y	106.10%
Book/sh	15.18	P/B	2.85	EPS next Y	73.90%	ROA	-0.77%	Short Interest	2.97M	Perf Year	57.28%
Cash/sh	3.63	P/C	11.90	EPS next 5Y	-	ROE	-0.83%	52W Range	18.61 - 46.00	Perf YTD	57.11%
Dividend Est.	-	P/FCF	57.73	EPS past 5Y	-10.52%	ROI	-0.78%	52W High	-6.04%	Beta	1.70
Dividend TTM	-	Quick Ratio	4.79	Sales past 5Y	34.42%	Gross Margin	64.93%	52W Low	132.24%	ATR (14)	1.79
Dividend Ex-Date	-	Current Ratio	5.08	EPS Y/Y TTM	79.63%	Oper. Margin	2.65%	RSI (14)	60.12	Volatility	4.27% 4.44%
Employees	815	Debt/Eq	0.02	Sales Y/Y TTM	23.95%	Profit Margin	-2.18%	Recom	1.67	Target Price	44.00
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	147.47%	Payout	-	Rel Volume	0.82	Prev Close	44.40
Sales Surprise	5.50%	EPS Surprise	486.42%	Sales Q/Q	28.58%	Earnings	Nov 06 AMC	Avg Volume	796.62K	Price	43.22
SMA20	3.52%	SMA50	15.23%	SMA200	55.98%	Trades		Volume	654,917	Change	-2.66%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-05-24	Downgrade	Goldman	Buy → Neutral	$38 → $37
Nov-15-24	Initiated	Wolfe Research	Outperform	$50
Oct-16-24	Initiated	UBS	Buy	$43
Oct-10-24	Initiated	Guggenheim	Buy	$40
Feb-23-24	Reiterated	Needham	Buy	$30 → $33
Jan-18-23	Downgrade	Raymond James	Outperform → Mkt Perform
Jan-05-23	Initiated	Scotiabank	Sector Outperform	$33
Jan-07-22	Initiated	Stephens	Overweight	$52
Nov-18-21	Resumed	Goldman	Buy	$60
Jun-15-21	Initiated	Raymond James	Outperform	$45
Feb-18-21	Resumed	Needham	Buy	$88
Jan-28-21	Initiated	Truist	Buy	$61
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight	$48
Sep-09-20	Initiated	Morgan Stanley	Underweight	$35
Jul-31-19	Initiated	Lake Street	Buy	$35
Jul-02-19	Initiated	Needham	Buy	$33
Nov-29-18	Downgrade	Janney	Buy → Neutral
Oct-31-18	Upgrade	Janney	Neutral → Buy
Nov-07-17	Downgrade	Piper Jaffray	Overweight → Neutral
Nov-07-17	Downgrade	Janney	Buy → Neutral

Show Previous Ratings

Dec-12-24 10:39AM	Why Veracyte, With 55% Growth In 2024, Is An Outlier In Cancer Diagnostics (Investor's Business Daily)
09:18AM	Veracyte (VCYT) Shares Rebounded in Q3 (Insider Monkey)
Dec-05-24 04:05PM	Veracytes Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN Prostate Cancer Guidelines (Business Wire)
Nov-27-24 04:51PM	Four Reasons To Watch This AI Play. A Fresh Breakout Is Just One. (Investor's Business Daily)
Nov-07-24 10:01AM	Veracyte Inc (VCYT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Outlook (GuruFocus.com)
06:10PM	Loading…
Nov-06-24 06:10PM	Veracyte (VCYT) Tops Q3 Earnings and Revenue Estimates (Zacks)
05:05PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2024 Financial Results (Business Wire)
Nov-05-24 07:43AM	What To Expect From Veracyte Inc (VCYT) Q3 2024 Earnings (GuruFocus.com)
Oct-30-24 05:00PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
Oct-16-24 06:43PM	Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024 (Business Wire)
Oct-09-24 05:07PM	Veracyte Inc (VCYT) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Raised Guidance (GuruFocus.com)
Oct-02-24 05:02PM	Vanguard Group Inc's Strategic Acquisition of Veracyte Inc Shares (GuruFocus.com)
08:20AM	New Data Presented at ASTRO 2024 Show that Veracytes Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men (Business Wire)
Sep-15-24 08:45AM	New Data Presented at ESMO 2024 Show that Veracytes Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer (Business Wire)
07:01PM	Loading…
Sep-06-24 07:01PM	Insider Sale: Chief Commercial Officer-CLIA John Leite Sells Shares of Veracyte Inc (VCYT) (GuruFocus.com)
Sep-05-24 11:31AM	Veracyte (VCYT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
Sep-04-24 04:05PM	Veracyte Appoints Brent Shafer and Tom Miller, Ph.D., to Its Board of Directors (Business Wire)
09:50AM	Here's Why Veracyte (VCYT) is a Strong Momentum Stock (Zacks)
Aug-26-24 05:30PM	Veracyte to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference (Business Wire)
09:00AM	Veracyte Named a Greater Bay Area Top Workplace by the San Francisco Chronicle (Business Wire)
04:36AM	Here's Why Baron Discovery Fund Increased its Holdings in Veracyte (VCYT) (Insider Monkey)
Aug-19-24 09:55AM	Veracyte (VCYT) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
Aug-15-24 09:50AM	Why Veracyte (VCYT) is a Top Momentum Stock for the Long-Term (Zacks)
Aug-14-24 09:15AM	Veracyte, Inc. (VCYT) Hit a 52 Week High, Can the Run Continue? (Zacks)
Aug-09-24 07:22PM	Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT) (GuruFocus.com)
Aug-08-24 09:09AM	Veracyte (VCYT) Q2 Earnings Beat Estimates, '24 Sales View Up (Zacks) +10.79%
Aug-07-24 02:08PM	Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish View (Benzinga) +23.97%
Aug-06-24 06:25PM	Veracyte (VCYT) Q2 Earnings and Revenues Beat Estimates (Zacks)
05:24PM	Veracyte: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Veracyte Announces Second Quarter 2024 Financial Results (Business Wire)
Jul-24-24 10:57AM	The 3 Best Personalized Nutrition Stocks to Buy Now (InvestorPlace)
Jul-19-24 12:01AM	Insider Sale: Director Jens Holstein Sells 5,000 Shares of Veracyte Inc (VCYT) (GuruFocus.com)
Jul-17-24 05:00PM	Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024 (Business Wire) -5.34%
04:48AM	Veracyte (VCYT) Stock Jumps 13.2%: Will It Continue to Soar? (Zacks)
Jun-21-24 09:55AM	Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High? (Zacks)
Jun-06-24 11:31AM	Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue? (Zacks)
Jun-03-24 04:05PM	Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors (Business Wire)
May-29-24 09:55AM	Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a Bet (Zacks)
09:30AM	Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for Investors (Zacks)
May-28-24 09:31AM	Here's Why MarketAxess Holdings (MKTX) Fell in Q1 (Insider Monkey)
08:47AM	Workiva (WK) Fell on Disappointing Forward Guidance (Insider Monkey)
08:32AM	Veracyte (VCYT) Fell Due to a Lack of Rising Profitability (Insider Monkey)
May-23-24 10:00AM	Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care (Zacks)
May-22-24 04:05PM	Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer (Business Wire)
May-21-24 09:59AM	Veracyte (VCYT) Up 6% Since Last Earnings: Will it Continue? (Zacks)
May-15-24 05:04PM	Veracyte to Participate in Upcoming Investor Conferences (Business Wire)
May-13-24 09:55AM	Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to Trade (Zacks) +5.29%
May-08-24 03:13PM	Veracyte, Inc. (NASDAQ:VCYT) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:55AM	Veracyte (VCYT) Reports Narrower Q1 Loss, Raises '24 Sales View (Zacks)
07:12AM	Q1 2024 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
03:48AM	Veracyte Inc (VCYT) (Q1 2024) Earnings Call Transcript Highlights: Strong Start with Revenue ... (GuruFocus.com)
May-07-24 10:55PM	VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:13PM	Veracyte: Q1 Earnings Snapshot (Associated Press Finance)
06:00PM	Veracyte Inc (VCYT) Q1 2024 Earnings: Surpasses Revenue Forecasts with Strong Test Performance (GuruFocus.com)
04:05PM	Veracyte Announces First Quarter 2024 Financial Results (Business Wire)
May-06-24 04:05PM	14 Studies Presented at AUA 2024 Show Decipher Tests Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding (Business Wire)
Apr-22-24 05:00PM	Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 (Business Wire)
08:30AM	New Study Shows Veracytes Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance (Business Wire)
Apr-16-24 08:30AM	Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 (Business Wire)
Apr-02-24 10:33AM	What Makes Veracyte (VCYT) a Lucrative Investment? (Insider Monkey) -5.22%
Feb-27-24 05:55PM	Veracytes Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines (Business Wire)
Feb-26-24 03:20PM	7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff (InvestorPlace) +6.22%
Feb-23-24 11:10AM	Veracyte, Inc. (NASDAQ:VCYT) Q4 2023 Earnings Call Transcript (Insider Monkey) -8.87%
07:43AM	Veracyte's (VCYT) Q4 Loss Widens, Gross Margin Expands (Zacks)
07:37AM	Q4 2023 Veracyte Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-22-24 06:05PM	Veracyte (VCYT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
05:03PM	Veracyte: Q4 Earnings Snapshot (Associated Press Finance)
04:40PM	Veracyte Inc (VCYT) Reports 22% Revenue Growth in 2023, Maintains Positive Cash Flow Outlook (GuruFocus.com)
04:05PM	Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results (Business Wire)
Feb-21-24 05:00PM	Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference (Business Wire)
Feb-08-24 08:00AM	Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 (Business Wire)
Feb-06-24 08:15AM	Veracyte Completes Acquisition of C2i Genomics (Business Wire)
Jan-08-24 08:00AM	Veracyte Announces Preliminary Full-Year 2023 Results, Acquisition of C2i Genomics to Add Minimal Residual Disease Capabilities to Its Novel Diagnostics Platform (Business Wire) +13.10%
Dec-12-23 04:30PM	Veracyte to Participate in the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire) +7.51%
Dec-01-23 04:05PM	Real-World Data Presented at SUO 2023 Show that Veracytes Decipher Genomic Classifier Identifies Patients Whose Prostate Cancer is Likely to Progress (Business Wire)
Nov-29-23 08:30AM	Clinical Validation Data Published in CHEST Demonstrate that Veracytes Percepta Nasal Swab Test Improves Lung Cancer Risk Assessment for Patients with Lung Nodules (Business Wire)
Nov-22-23 08:30AM	Veracyte Announces Seven Posters Highlighting Clinical Value of Decipher Prostate Genomic Testing To be Presented at SUO 2023 (Business Wire)
Nov-08-23 04:39PM	Veracyte, Inc. (NASDAQ:VCYT) Q3 2023 Earnings Call Transcript (Insider Monkey) -7.26%
Nov-07-23 04:57PM	Veracyte: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Veracyte Announces Third Quarter 2023 Financial Results (Business Wire)
04:00PM	Veracyte Announces In Vitro Diagnostic Agreement with Illumina to Broaden Availability of Its Tests for Patients Globally (Business Wire)
Nov-02-23 08:15AM	Veracyte to Participate in the Stephens Annual Investment Conference (Business Wire) +6.13%
Oct-27-23 08:30AM	Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development (Business Wire)
Oct-26-23 02:50PM	7 Undervalued Stocks That Analysts Love Right Now (InvestorPlace)
Oct-17-23 08:15AM	Veracyte to Release Third Quarter 2023 Financial Results on November 7, 2023 (Business Wire)
Oct-16-23 10:43AM	16 Best Stocks to Buy and Hold for the Next 15 Years According to Cathie Woods Portfolio (Insider Monkey)
Oct-12-23 09:00AM	New Data Presented at CHEST 2023 Demonstrate the Clinical Utility of Veracytes Envisia Genomic Classifier for Patients with Interstitial Lung Disease (Business Wire) -5.82%
Oct-04-23 04:05PM	New Data from Phase 3 Trial Further Validate Prognostic Value of Veracytes Decipher Prostate Genomic Classifier (Business Wire)
Sep-28-23 04:05PM	New Data Presented at the 2023 ATA Annual Meeting Demonstrate that Veracytes Afirma-Based Testing Can Uncover Key Molecular Hallmarks of Thyroid Cancer (Business Wire)
08:15AM	Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 (Business Wire)
Sep-27-23 09:00AM	Veracyte Names Phillip G. Febbo, M.D., as Chief Scientific Officer and Chief Medical Officer (Business Wire)
Sep-21-23 04:05PM	Veracyte Announces Novel Afirma-Based Findings that Advance Molecular Understanding of Thyroid Cancer to Be Presented at the 2023 ATA Annual Meeting (Business Wire)
Sep-07-23 04:05PM	Veracyte Names Marie-Claire Taine, Ph.D., as General Manager of Its IVD Business Unit To Advance Global Expansion of the Companys Tests (Business Wire)
Sep-06-23 08:15AM	Veracyte and Gustave Roussy Announce Collaboration to Help Biopharmaceutical Companies Accelerate Development of Novel Cancer Therapies (Business Wire)
Sep-02-23 06:15AM	Is This Underfollowed Genetic Diagnostics Stock a Buy for Growth Investors? (Motley Fool)
Aug-29-23 08:15AM	Veracyte to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference (Business Wire)
Aug-22-23 08:15AM	Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer (Business Wire)
Aug-15-23 04:15PM	Veracyte Earns Top Workplace Awards in the San Francisco Bay Area and San Diego (Business Wire)
Aug-08-23 06:05PM	Veracyte (VCYT) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +7.04%

Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MARC STAPLEY	Director	Dec 13 '24	Proposed Sale	44.40	5,590	248,196		Dec 13 04:27 PM
Febbo Phillip G.	Chief Scientific & Med Officer	Dec 04 '24	Sale	44.09	3,934	173,447	82,414	Dec 06 04:34 PM
McGuire Annie	SVP, General Counsel	Dec 04 '24	Sale	44.02	18,699	823,179	72,869	Dec 06 04:34 PM
PHILLIP G FEBBO	Officer	Dec 04 '24	Proposed Sale	44.09	1,311	57,802		Dec 05 05:24 PM
Leite John	Chief Commercial Officer-CLIA	Dec 03 '24	Sale	43.25	1,050	45,408	73,810	Dec 04 04:59 PM
Chambers Rebecca	Chief Financial Officer	Dec 03 '24	Sale	43.23	7,000	302,622	114,037	Dec 04 04:59 PM
Wygant Jonathan	VP, Chief Accounting Officer	Dec 03 '24	Sale	43.36	956	41,452	40,270	Dec 04 04:59 PM
PHILLIP G FEBBO	Officer	Dec 04 '24	Proposed Sale	43.66	2,623	114,520		Dec 04 04:38 PM
ANN MCGUIRE	Officer	Dec 04 '24	Proposed Sale	43.66	18,699	816,398		Dec 04 04:35 PM
REBECCA CHAMBERS	Officer	Dec 03 '24	Proposed Sale	44.12	7,527	332,091		Dec 03 04:32 PM
JOHN LEITE	Officer	Dec 03 '24	Proposed Sale	44.12	1,050	46,326		Dec 03 04:31 PM
Wygant Jonathan	VP, Chief Accounting Officer	Nov 27 '24	Sale	42.89	5,032	215,834	42,313	Nov 29 02:28 PM
EASTHAM KARIN	Director	Nov 19 '24	Sale	38.34	14,731	564,768	18,497	Nov 21 04:36 PM
KARIN EASTHAM	Director	Nov 19 '24	Proposed Sale	36.71	14,731	540,775		Nov 19 04:23 PM
Chambers Rebecca	Chief Financial Officer	Nov 12 '24	Sale	38.34	15,275	585,663	124,501	Nov 14 04:35 PM
EPSTEIN ROBERT S	Director	Nov 12 '24	Option Exercise	8.04	15,000	120,600	59,598	Nov 14 04:35 PM
EPSTEIN ROBERT S	Director	Nov 12 '24	Sale	38.32	15,000	574,830	44,598	Nov 14 04:35 PM
ROBERT S EPSTEIN	Director	Nov 12 '24	Proposed Sale	38.89	15,000	583,350		Nov 12 04:29 PM
REBECCA CHAMBERS	Officer	Nov 12 '24	Proposed Sale	38.89	15,275	594,045		Nov 12 04:29 PM
JONES EVAN/ FA	Director	Sep 19 '24	Sale	35.23	5,173	182,263	0	Sep 23 04:23 PM
Leite John	Chief Commercial Officer-CLIA	Sep 04 '24	Sale	29.78	5,479	163,159	76,174	Sep 06 04:18 PM
JOHN LEITE	Officer	Sep 04 '24	Proposed Sale	30.29	5,479	165,959		Sep 04 04:17 PM
JONES EVAN/ FA	Director	Aug 13 '24	Option Exercise	10.41	8,486	88,339	54,800	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 13 '24	Sale	32.20	27,188	875,565	5,173	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 13 '24	Sale	32.20	20,457	658,801	34,343	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 12 '24	Sale	30.00	101	3,031	32,361	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 12 '24	Sale	30.01	99	2,971	46,314	Aug 14 05:09 PM
JONES EVAN/ FA	Director	Aug 09 '24	Option Exercise	10.41	300	3,123	47,445	Aug 13 04:38 PM
JONES EVAN/ FA	Director	Aug 09 '24	Sale	30.03	1,032	30,990	46,413	Aug 13 04:38 PM
JONES EVAN/ FA	Director	Aug 09 '24	Sale	30.03	746	22,402	32,462	Aug 13 04:38 PM
Holstein Jens	Director	Aug 07 '24	Sale	29.00	5,000	145,000	27,878	Aug 09 04:47 PM
JONES EVAN/ FA	Director	Aug 07 '24	Option Exercise	10.41	1,214	12,638	50,288	Aug 09 04:47 PM
JONES EVAN/ FA	Director	Aug 07 '24	Sale	30.32	5,108	154,883	45,180	Aug 09 04:47 PM
Evan Jones	Director	Aug 07 '24	Proposed Sale	27.05	59,904	1,620,403		Aug 07 07:52 PM
EASTHAM KARIN	Director	Jul 16 '24	Sale	25.00	7,500	187,500	33,228	Jul 18 06:25 PM
Leite John	Chief Commercial Officer-CLIA	Jul 16 '24	Sale	25.00	1,277	31,925	82,968	Jul 18 06:25 PM
Holstein Jens	Director	Jul 16 '24	Sale	24.50	5,000	122,500	32,878	Jul 18 06:25 PM
EASTHAM KARIN	Director	Jun 11 '24	Sale	20.59	3,870	79,683	29,255	Jun 13 04:24 PM
Bhanji Muna	Director	Jun 10 '24	Sale	20.32	3,870	78,634	23,105	Jun 11 04:22 PM
EASTHAM KARIN	Director	Jun 07 '24	Option Exercise	10.41	2,500	26,025	35,625	Jun 11 04:21 PM
EASTHAM KARIN	Director	Jun 07 '24	Sale	20.97	2,500	52,425	33,125	Jun 11 04:21 PM
Bhanji Muna	Director	May 28 '24	Sale	21.00	1,539	32,319	26,975	May 30 04:41 PM
EASTHAM KARIN	Director	Apr 01 '24	Option Exercise	13.19	10,000	131,900	43,125	Apr 02 04:17 PM
EASTHAM KARIN	Director	Apr 01 '24	Sale	21.65	10,000	216,528	33,125	Apr 02 04:17 PM
JONES EVAN/ FA	Director	Mar 01 '24	Option Exercise	13.19	10,000	131,900	47,601	Mar 05 05:28 PM
JONES EVAN/ FA	Director	Mar 01 '24	Sale	24.36	10,000	243,599	37,601	Mar 05 05:28 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VCYT

Veracyte Inc

Upgrade your FINVIZ experience